Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [157]
elearning [19]
The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients...
Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy
The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer ( Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy )
11 Jun 2020
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA
Perioperative novel systemic immunotherapy-based approaches in urinary cancers ( Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA )
9 Jun 2020
ASCO 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO 2020: Updates in renal cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2020
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to...
Prof Benoit You - Hospices Civils de Lyon, Lyon, France
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )
5 Jun 2020
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H...
Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris...
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer ( Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, France )
5 Jun 2020
Highlights from ASCO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
5 Jun 2020
New emerging treatment options and targeted therapies for bladder cancer
Dr Arlene Siefker-Radtke and Dr Yohann Loriot
New emerging treatment options and targeted therapies for bladder cancer ( Dr Arlene Siefker-Radtke and Dr Yohann Loriot )
4 Jun 2020
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
2 Jun 2020
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer
Prof Benjamin Besse and Dr Alex Spira
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer ( Prof Benjamin Besse and Dr Alex Spira )
2 Jun 2020
Ensuring quality care for breast cancer patients globally
Dr Didier Verhoeven - University of Antwerp, Antwerp, Belgium
Ensuring quality care for breast cancer patients globally ( Dr Didier Verhoeven - University of Antwerp, Antwerp, Belgium )
1 Jun 2020
Teclistamab for patients with heavily pretreated relapsed or refractory...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
1 Jun 2020
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy...
Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA )
31 May 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation